AGIO
Agios Pharmaceuticals Inc

2,860
Mkt Cap
$1.87B
Volume
3.64M
52W High
$62.45
52W Low
$22.24
PE Ratio
-3.63
AGIO Fundamentals
Price
$25.24
Prev Close
$24.57
Open
$24.66
50D MA
$39.91
Beta
1.14
Avg. Volume
552,851.22
EPS (Annual)
$11.64
P/B
1.15
Rev/Employee
$74,790.98
Loading...
Loading...
News
all
press releases
Agios Pharmaceuticals, Inc. $AGIO Shares Acquired by CenterBook Partners LP
CenterBook Partners LP increased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 124.0% during the 2nd quarter, according to its most recent 13F filing with the Securities...
MarketBeat·51m ago
News Placeholder
More News
News Placeholder
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $20.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. dropped their price objective on shares of Agios Pharmaceuticals from $37.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday...
MarketBeat·15h ago
News Placeholder
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at Wall Street Zen
Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·1d ago
News Placeholder
Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading Volume After Analyst Upgrade
Agios Pharmaceuticals (NASDAQ:AGIO) Sees Unusually-High Trading Volume After Analyst Upgrade...
MarketBeat·2d ago
News Placeholder
HC Wainwright Lowers Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $48.00
HC Wainwright lowered their price objective on Agios Pharmaceuticals from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Thursday...
MarketBeat·2d ago
News Placeholder
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to "Sector Perform" at Royal Bank Of Canada
Royal Bank Of Canada cut Agios Pharmaceuticals from an "outperform" rating to a "sector perform" rating and set a $28.00 target price on the stock. in a report on Wednesday...
MarketBeat·3d ago
News Placeholder
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
Zacks·3d ago
News Placeholder
Stock Traders Purchase High Volume of Agios Pharmaceuticals Call Options (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 8,407 call options on the stock. This is...
MarketBeat·3d ago
News Placeholder
Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 12-Month Low - Here's Why
Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 1-Year Low - Here's What Happened...
MarketBeat·3d ago
News Placeholder
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug
Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the mixed Phase 3 readout.
Stocktwits·3d ago

Latest AGIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.